SOPHiA GENETICS Expands Partnership with Canadian Oncology Lab OncoHelix

SOPHiA GENETICS and OncoHelix Strengthen Collaboration

SOPHiA GENETICS, a leading cloud-native software company in the healthcare sector, has announced an expansion of its partnership with OncoHelix, a prominent molecular diagnostics laboratory based in Canada 1

1

. This strategic move is set to bolster cancer care by leveraging advanced genomic analysis technologies.

Enhanced Cancer Care Through Technology

The collaboration centers around the implementation of SOPHiA GENETICS' innovative SOPHiA DDM™ Platform at OncoHelix 2

2

. This platform is designed to streamline and enhance the analysis of complex genomic data, particularly in the field of oncology. By adopting this technology, OncoHelix aims to significantly improve its capacity to process and interpret genetic information related to various types of cancers.

Expanding Diagnostic Capabilities

OncoHelix plans to utilize the SOPHiA DDM™ Platform to support multiple applications in cancer diagnostics 1

1

. These include:

1. Myeloid solutions
2. Solid tumor solutions
3. Hereditary cancer testing

This comprehensive approach will enable OncoHelix to offer a wider range of diagnostic services, potentially benefiting a larger number of cancer patients across Canada.

Data-Driven Insights for Personalized Treatment

The partnership is expected to enhance OncoHelix's ability to provide data-driven insights to healthcare providers 2

2

. By leveraging SOPHiA GENETICS' advanced analytics capabilities, oncologists will have access to more accurate and detailed genetic information. This, in turn, can lead to more personalized treatment strategies for cancer patients, potentially improving outcomes and quality of care.

Global Network and Knowledge Sharing

An important aspect of this collaboration is OncoHelix's integration into SOPHiA GENETICS' global network 1

1

. This network comprises numerous healthcare institutions worldwide that use the SOPHiA DDM™ Platform. By joining this community, OncoHelix will have the opportunity to share knowledge and insights with other leading institutions, fostering a collaborative approach to advancing cancer research and treatment.

Industry Impact and Future Prospects

The expanded relationship between SOPHiA GENETICS and OncoHelix represents a significant development in the field of precision medicine for oncology 2

2

. As more healthcare providers adopt advanced genomic analysis tools, the potential for improved cancer diagnostics and personalized treatment plans continues to grow. This partnership serves as an example of how technology and data-driven approaches are shaping the future of cancer care.